Podcasts about Phage therapy

 Finally, there is a remedy, even invented 100 years ago…Called Phages bacterial treatmentWhat is Phage Therapy?Phages, formally known as bacteriophages, are viruses that solely kill and selectively target bacteria. They are the most common biological entities in nature and have been shown to effectively fight and destroy multi-drug resistant bacteria. Namely, when all antibiotics fail, phages still succeed in killing the bacteria and may save a life from an infection.The phage virus needs a host where it can spread its eggs. The host is that specific bacteria that you want to kill. The phage virus injects its eggs inside that bacteria. The eggs grow to that phage virus and kill the bacteria… Thousands of new phage viruses search for the correct bacteria …  Imagine that… After a short time, all the bacteria are killed. The problem is to find the correct phage virus to kill that specific bacteria or even the Superbug. And that can be done because you find the phage virus everywhere… At least in garbage places or water filtering systems.  The main concern for all of us now is the alarming rate of increasing 'superbugs' that are resistant to most — if not all — antibiotics, as well as the impact they will have on human health and the longevity of life. These issues, combined with a lack of regulation to approve the process of phage therapy for anything less than an absolute, no-alternative emergency, pose a serious concern for us. We hope that through our work here at PATH, we can make this treatment more widely available to save lives where no other treatments could.My Video: How to kill dangerous bacteria like the Superbugs? https://youtu.be/H_BSLJ8bzfQMy Audio: https://divinesuccess.net/wp-content/uploads/2021/Podcast4/How-to-kill-dangerous-bacteria-like-the-Superbugs.mp3

The infections disease landscape is constantly changing - challenging our standard treatments. Can new - as well as ancient - therapies be the answer? Hear from experts on the cutting edge of phage therapy, HIV/AIDS research and cancer care about what is on the horizon to improve human health. Series: "Stem Cell Channel" [Health and Medicine] [Show ID: 39982]

The infections disease landscape is constantly changing - challenging our standard treatments. Can new - as well as ancient - therapies be the answer? Hear from experts on the cutting edge of phage therapy, HIV/AIDS research and cancer care about what is on the horizon to improve human health. Series: "Stem Cell Channel" [Health and Medicine] [Show ID: 39982]

The infections disease landscape is constantly changing - challenging our standard treatments. Can new - as well as ancient - therapies be the answer? Hear from experts on the cutting edge of phage therapy, HIV/AIDS research and cancer care about what is on the horizon to improve human health. Series: "Stem Cell Channel" [Health and Medicine] [Show ID: 39982]

The infections disease landscape is constantly changing - challenging our standard treatments. Can new - as well as ancient - therapies be the answer? Hear from experts on the cutting edge of phage therapy, HIV/AIDS research and cancer care about what is on the horizon to improve human health. Series: "Stem Cell Channel" [Health and Medicine] [Show ID: 39982]

The infections disease landscape is constantly changing - challenging our standard treatments. Can new - as well as ancient - therapies be the answer? Hear from experts on the cutting edge of phage therapy, HIV/AIDS research and cancer care about what is on the horizon to improve human health. Series: "Stem Cell Channel" [Health and Medicine] [Show ID: 39982]

The infections disease landscape is constantly changing - challenging our standard treatments. Can new - as well as ancient - therapies be the answer? Hear from experts on the cutting edge of phage therapy, HIV/AIDS research and cancer care about what is on the horizon to improve human health. Series: "Stem Cell Channel" [Health and Medicine] [Show ID: 39982]

The infections disease landscape is constantly changing - challenging our standard treatments. Can new - as well as ancient - therapies be the answer? Hear from experts on the cutting edge of phage therapy, HIV/AIDS research and cancer care about what is on the horizon to improve human health. Series: "Stem Cell Channel" [Health and Medicine] [Show ID: 39982]

The infections disease landscape is constantly changing - challenging our standard treatments. Can new - as well as ancient - therapies be the answer? Hear from experts on the cutting edge of phage therapy, HIV/AIDS research and cancer care about what is on the horizon to improve human health. Series: "Stem Cell Channel" [Health and Medicine] [Show ID: 39982]

Diane Shader Smith's daughter Mallory died from complications of cystic fibrosis 6 years ago. She was 25 years old. Diane initially published her daughter's diary, "Salt in My Soul".  This book gave insight into how Mallory was feeling during her CF fight. Her deepest thoughts, and life lessons.Diane Shader Smith  is now releasing a second book on behalf of her daughter, "Diary of a dying Girl".  The title honestly may sound depressing, but as Diane explains, it is a wakeup call about our public health crisis and is an empowering story. Mallory's writing is so beautiful. And I can tell you, you won't be sad reading her book, you'll be inspired. In this podcast Diane explains that it's our job to raise awareness about Phage Therapy, and about the dangers of antimicrobial resistance (AMR). Something that everyone should become educated about, whether CF is your disease space, or not.You can buy Mallory's book here:  https://diaryofadyinggirl.com    All the money goes to AMR research through Mallory's Legacy Fund. You can also sign up, and tell your story at the Global AMR Diary: https://www.globalamrdiary.org Please like, subscribe, and comment on our shows, wherever you get your podcasts.Please consider making a donation: https://thebonnellfoundation.org/donate/The Bonnell Foundation website:https://thebonnellfoundation.orgEmail us at: thebonnellfoundation@gmail.com Thanks to our sponsors:Vertex: https://www.vrtx.comViatris: https://www.viatris.com/en

Happy Tuesday Everyone and Welcome back to the latest episode of Phage Therapy Today! Phage science is awesome, the business is growing, and the numbers on paper are looking great. But along with this excitement, we must realize the end goal is to save lives and improve clinical outcomes. The truth is phage therapy is still very far from accessible to the general public today. There are many reasons for this, and the lack of information and community available to the general public and doctors is definitely a major contributing factor. Because phage therapy is not yet the standard of care and is considered experimental, doubt from doctors and patients can delay the start of phage therapy treatment. In this week's episode, Christopher Schaffer shares his story of how he saved his own life by going on a journey where he took the lead in finding a cure for his MDR infection. He did tons of research on his own, reaching out to all the help  he could get, and navigating through difficult situations related to Covid and the Ukraine war. The amount of courage, determination, and faith he demonstrated is awe-inspiring. Let's give it a listen! To bridge this gap, I am unofficially announcing the formation of a nonprofit organization led by Christopher Schaffer, Professor Irene Chen, and myself. Our aim is to create a community for patients and doctors looking into phage therapy. The goal is to provide information on success stories from past patients to build trust in phage therapy, connect with therapeutic resources, and provide support to all going through AMR infections, ensuring you are not alone out there. As a first step, I would like people to re-post, @doctors, and patients who require phage therapy resources to join our Discord group at: https://discord.gg/gtrX5ZpE. We would also like everyone else passionate about phage therapy to join and comment in the “volunteers” and “general” channels only.

In this Part 2 of the Alloutcoach podcast episode focused on phage therapy to fight infections and antimicrobial resistance, I spoke to the Chief Physician at the globally leading center of excellence of an alternative, effective treatment approach to antibiotics, Dr. Dea Nizharadze at the Eliava Phage Therapy Center (EPTC) based in Tbilisi, Georgia. She explains the basic principles of phage treatments, its unique qualities, advantages and real-world clinical examples of methods and types of patients and infections this personalized therapy specifically targets. 0:00 Episode Introduction 1:42 Why the Republic of Georgia is a global leader in phage therapy 2:39 How phage therapy works in bacterial infections?Eliava Phage Therapy Center (EPTC) was founded in 1923 by Professor George Eliava who had collaborated with Felix D'Herelle, who had discovered phages, and while most other countries turned to antibiotics only, it is the only institution in the world that has continued to research bacteriophages without a pause of even one day since its inception and therefore collected the greatest research and real-world clinical experience with phages. 5:34 How do phages work to eradicate or stop further growth of bacteria? Phages are biological "weapons" against bacteria, namely viruses that target specific microbes only, without destroying the "good" bacteria or microbiota. They are naturally occurring substances and have no safety concerns. In some patients with antimicrobial resistance phage therapy enables improvement in sensitivity. 10:42 Synergistic effect of phage combination therapy with antibiotics 11:58 Phage Therapy Doisng and Success Factors 15:14 Length of phage treatmentIn chronic infections phage therapy may divided into 3 stages and last 15-20 days, and varies by nature and severity of disease. Patient treatment includes days off therapy, or holidays, however, bacterial analysis is continued and patient condition is monitored throughout the entire course of treatment. Success of therapy is indicated when bacterial titers and virulence decrease or bacteria are eradicated. Patient's objective and subjective signs and symptoms often vary throughout response to therapy. 16:42 Phage Product Variability and Market Availability How do we ensure educating patients to access the correct, most appropriate therapy for their infections 17:35 Multi-disciplinary personalized team care and telemedicine 19:53 Steps for patients outside of Georgia to access phage therapy via telemedicine? 24:04 Affordability and access to phage treatments 25:23 How to contact Eliava Phage Therapy Center

In this episode, hosts Josh Davis (Newcastle, Australia) and Angela Huttner (Geneva, Switzerland) interview the phage ‘microbiologist-clinician duo', Drs. Shawna McCallin and Lorenz Leitner (Balgrist Hospital, Zurich, Switzerland). They explore the history of phages, the process of bringing phage therapy to a patient, potential resistance to phages, availability of individualized therapy versus phage cocktails, and the place of phage therapy in the future. Drs. Leitner and McCallin reflect on the challenges and lessons of their recently published randomized trial comparing phage therapy to antibiotics for urinary tract infection. Episode peer-reviewed by Dr. Olivia Funk of Long Island University. LiteratureLeitner L, Ujmajuridze A, Chanishvili N et al.  Intravesical bacteriophages for treating urinary tract infections in patients undergoing transurethral resection of the prostate: a randomised, placebo-controlled, double-blind clinical trial. Lancet Infect Dis. 2021 Mar;21(3):427-436. doi: 10.1016/S1473-3099(20)30330-3. 

House Doctor Raj Bhardwaj says a woman in Ottawa recently became the first person in Canada to benefit from what's called “Phage Therapy”

House doctor Mike Simon speaks with host Julia Wright about phage therapy and why are researchers hopeful that the experimental treatment could help to make antibiotics more effective. 

Phage therapy has gained a lot of traction but the challenges created by this approach have not been properly assessed at a big scale. We often read about therapy successes on isolated cases but, rarely, we read or hear about failures. AAC recently published a case series of patients who failed phage therapy. Today, we will discuss this topic with the principal investigator on the research. Topics discussed: Phage therapy as an approach for MDR bacteria. The challenges of phage therapies. Issues that can influence the success of phage therapy Guest: Saima Aslam, MBBS. Director, Solid Organ Transplant Infectious Diseases Service, Professor of Medicine, University of California, San Diego. Article: Pseudomonas aeruginosa ventricular assist device infections: findings from ineffective phage therapies in five cases https://journals.asm.org/doi/10.1128/aac.01728-23 Questions Answered: How are we doing with phage therapy at this point? What are the challenges to deploy phage therapy in clinical settings? The 5 cases of failure of phage therapy in patients with LVADs summarized What factors did Dr. Aslam identify that were related with the failure? How do you develop neutralization against phages and how can you prevent it?   Bacterial isolates with varying phage susceptibility, how can this be detected? What did Dr. Aslam learn? Future research This episode is brought to you by the Antimicrobial Agents and Chemotherapy journal available at aac.asm.org. If you plan to publish in AAC, ASM Members get up to 50% off publishing fees. Visit asm.org/membership to sign up. Visit journals.asm.org/journal/aac to browse issues and/or submit a manuscript.

An experimental treatment is providing some hope for people dealing with antibiotic resistant infections. The first person in Canada to receive phage therapy says it saved her life. It's not available yet outside clinical trials. Dr. Peter Lin explains.

​An Ottawa-area woman has become the first person in Canada to receive an experimental treatment for a chronic joint infection. ​J​eanne Armstrong spoke to Dr. Peter Lin ​about phage-therapy and why doctors are hopeful about the potential of this experimental therapy in treating antibiotic resistant infections.

Dr. Diaz Vera, Infectious Diseases Fellow at the University of South Florida Division of Infectious Diseases, presents a companion lecture to his original talk on bacteriophage therapy. Because of the rising tide of antimicrobial resistance, many experts believe that we are entering the post-antibiotic era in medicine. As a result, researchers are exploring phage-antimicrobial synergy in an attempt to make our antibiotic armamentarium go farther. Dr. Diaz elaborates on the application of phage-antimicrobial synergy and provides examples of phage therapy utilized in the clinical setting. For Dr. Diaz’s original talk, please click here: Intro to Bacteriophage therapy

Panel Beater and Dr. Sharma speak to filmmaker Emma Watts and Dr. Fernando Gordillo Altamirano about Last Chance to Save a Life, a documentary examining how, as antibiotics fail and superbugs are on the rise, phage therapy could be the answer the medical world is looking for.Later in the show, Panel Beater and Dr. Sharma speak with Dr. Margaret Nixon and (soon-to be Dr.) Ella Kofoedl of Swinburne University on their research into prisoners who have dementia, and how it presents differently in the regulated world of prison life.

As many reflect on the past few years of the pandemic and continue thinking about emerging threats of the future, it's important to bring awareness to that very topic, the future, and what's on the horizon in public health. Today's episode is Part 3 of a series that focuses on the emerging threat of antimicrobial resistance, which has been deemed by The World Health Organization as one of the top 10 global public health threats facing humanity. The episode digs deeper into innovations happening globally to help defeat superbugs and evolve the applications of Phage Therapy as well as deepening connectivity to the broader healthcare community. This episode's guest is Jessica Sacher, PhD, a Canadian Phage Microbiologist and Co-Founder of Phage Directory as well as Phage Australia. The Phage Directory goal is founded in helping doctors find phage scientists willing to share their phages to rescue patients dying from antibiotic-resistant infections. Phage Directory is now the global phage community's central source of news & connectivity that supports thousands of phage professionals, from 80+ countries, helping clinicians source phages for their patients while also helping organizations manage, grow, and learn from their phage collections. Listen in with us as we continue to explore this evolving science and how it's innovations will continue to create alternative paths to treat a variety of health conditions as told from scientists that are influential in the space. Other topics range from the significance of climate change as a contributor to emerging human viruses, to how gene editing technologies are helping to evolve precision medicine and designer therapies, to the future of phage applications across a range of practical applications. For more details visit TechLink Health on the web or connect with Jessica and Phage Directory @ Phage.Directory or

Discover 'The Good Virus,' and 'The Master Builder,' books that highlight the forgotten promise of phage therapy and delve into the new science of the cell. This podcast unravels stories of quirky scientists and transformative discoveries that are bringing attention back to old discoveries with the potential to combat stubborn ailments and reveal fascinating new truths about biology. Tune in as we explore the origins, the intriguing history, and the potential future of phage therapy, and discuss the ways it could help in fighting antibiotic resistance.

TWiM explains personalized aerosilized phage therapy for a chronic lung infection, and using the combination of antibiotic and a DNA molecule that binds alpha-gal to reduce S. aureus infection in vivo. Hosts: Vincent Racaniello and Michael Schmidt Subscribe to TWiM (free) on Apple Podcasts, Google Podcasts, Stitcher, Android, RSS, or by email. Become a Patron of TWiM! Links for this episode: Aerosolized phage therapy (Nat Comm) Alpha-gal aptamer and vancomycin for MRSA (Microorg) Alpha-gal syndrome (Front Allergy) Natural antibody protects against viral infection (virology blog) Music used on TWiM is by Ronald Jenkees. Send your microbiology questions and comments to twim@microbe.tv

 Sugar replacements, known generally as artificial sweeteners or non-nutritive sweeteners, have been in the news a lot. Rising concerns exist about safety and the effects of the sweeteners on many key features of health, including the microbiome. We need the help of talented scientists to sort through this complex web of information. Today's guest, Professor Eran Elinav, has done some of the seminal research in this area. He's an expert on systems immunology at the Weizmann Institute of Science in Israel. Interview Summary So back in 2014, you and your colleagues published a study in the prestigious journal Nature showing that sweeteners could induce glucose intolerance - a highly concerning finding, What's more, they did so by changing the microbiome. Would you tell us a little bit more about this study and what subsequent researchers found. In the study that published in Nature back in 2014, we explored the consumption of several kinds of artificial sweeteners when administered to mice. We wanted to ask a very simple but important question - are dose formulations of hypersweet compounds, which are so massively consumed by humans, in fact being responded to by our gut microbes. We know from our other studies that gut microbes contain a very well-developed machinery that enables them to respond and to digest multiple very complex formulations of food. We asked ourselves whether these seemingly inherent compounds could induce changes in the gut microbiome that could impact the health of these mice. And indeed, when we tested this, we mainly focused on saccharin, but in several experiments saw that could also be true for other common artificial sweeteners. We saw that the gut microbiome of mice being given saccharin in different concentrations, (using different strains of mice and different obesity conditions) were indeed capable of reacting to saccharin, changing their microbiome composition and behavior accordingly, and in some cases, resulting in a very surprising, counterintuitive worsening of glucose control towards diabetes. That was very concerning to us, because many millions of people worldwide consume artificial sweeteners with an aim of satisfying their sweet tooth without having to pay the caloric price. Especially people who are prone or already suffer prediabetes or even type II diabetes. What we could show was that the gut microbiome in some configurations could actually drive a disturbed control of sugar levels in the blood of these mice, which could suggest that in some cases, the gut microbiome could actually be bad for you when you consume artificial sweeteners in terms of your sugar management. That is a landmark study by any standard, so congratulations for doing such important science. That was back in 2014. So what has research shown since then?  We were able to prove in that study that consumption of artificial sweeteners was not only associated with changes in the microbiome and with the trend towards altered sugar control, but it was actually costly. We did this by transferring microbiomes from mice that were exposed to saccharin or to other artificial sweeteners into mice that do not have any microbiome of their own. They're called germ-free mice. We could see that these recipient mice who never consumed artificial sweeteners were developing the same exact disturbances in their sugar control just by the exposure to microbes that were previously exposed to artificial sweeteners. Now, this was very surprising, very important, and also caused a lot of backfire from the industry as one would expect. But it led to an array of follow up studies by multiple groups, mainly in other mice models and utilizing other formulations of artificial sweeteners, which basically suggested that our observations were correct. Artificial sweeteners were not inert when given to mice in different contexts and disease states. Now, the biggest limitation of our original study and all these many follow up studies was that all of these experiments were conducted in mice. The billion-dollar question was, can we recapitulate these findings at least, to some extent, in the human setting? This prompted us to perform a very ambitious human clinical trial which took multiple years to complete. It was finally published a year ago. The take home from that study which focused on all four commonly consumed artificial sweeteners was the concept that we've highlighted almost a decade ago - it was correct when applied to humans. Those findings raise alarms on many different levels. I appreciate you sharing that information with us. Recently, the World Health Organization has expressed concern about the sweeteners and their impact on people's ability to control body weight and health, and even risk for cancer. One of the counters from people who are in favor of these sweeteners is that the doses provided in these studies are many times what a human might ordinarily consume. What do you say to that? I will say two important things. First, this may have been true in previous studies a decade ago in which we all started by testing artificial sweeteners at relatively high doses. However, with years of follow-up studies and the expanded field of the doses of tested artificial sweeteners that were in many cases, reduced to those below the recommended daily allowance in humans. And, in the controlled clinical trials published a year ago, doses of four artificial sweeteners that we supplemented our participants were well below the recommended daily allowance. And still in some people, we could see that these seemingly inherent compounds were able to reproducibly change the microbiome and to change to our configuration which could induce alterations in blood sugar control in these individuals. When those microbiomes were transferred to mice that had never seen artificial sweeteners, the microbiome integrations could also induce identical disturbances of blood sugar control in transfer mice. So, I think that our studies and plethora of other studies generate knowledge suggesting that artificial sweeteners may not be natural to the human body even when consumed in conservative doses. Well, thanks for that clarification. You mentioned some pushback from industry. Tell me what form that took. Was there a particular player in industry that was doing the pushback? Did you think that their concerns were valid? Well, I think that it is a natural part of the evolution of a set of discoveries that have a direct impact on human health and human nutrition. And also, of course, economic considerations. Some of the claims were less than fair, and others were more relevant. One needs to understand, and I'm saying this both as a physician and as a scientist, especially given our early studies, that you can make the best effort that you can and comprehensively try to tackle a question. But there are always things people can claim that were not done or should be done better. Science is not a one-shot profession. We come up with a discovery and then we build upon it, and others also come in, validate it, build upon it, and this was the process. So, I take everything with love. Many other people have experienced a healthy discussion with the industry, and I think we've all matured into understanding, at least in our group, we are not against artificial sweeteners or any other food compound. We are just keen and interested in learning how different food compounds including artificial sweeteners, impact our body in unforeseen ways, and we focus on the gut microbiome. This huge and poorly explored ecosystem, which we now understand is an integral part of our body, has amazing biochemical capacities to degrade and respond to almost any substance. With artificial sweeteners, I think that this revelation is actually very helpful to the industry because with this knowledge, and knowledge that is added by others, we are hopeful that by understanding that artificial sweeteners are not inert to the human bodies, we would be able, together with the industry or with whoever is interested in helping this effort, understand which formulations are safer than others. Which doses are safer than others; and which are the human populations at risk, who should think twice before they consume these compounds. While others could consume them and enjoy them with relatively little risk. I think this maturation of our knowledge and maturation of the field is, in general, a very positive one. So, with respect to the impact of these sweeteners on the microbiome, is there reason to have special concern about children? When we conduct human clinical trials, we're always hypersensitive about special populations at risk such as children, people who are incarcerated, and so on and so forth. We usually tend at least in groundbreaking first human trials, such as the one that we've conducted with artificial sweeteners, we try to avoid these at-risk populations just so our initial observations are based on populations that are not at special risks. So, children, as you know, are always a special population that we're even more concerned about than a general population. Our own setting was not inclusive of children, though our inclusion criteria included healthy adults 18 years of age and older. So, with respect to children, I can say that our own data did not explore them to date. But in general, we are always especially concerned about children. Any potential metabolic perturbation during that critical growth window for children is of special medical concern to us. Let me ask you one final, big-picture question. The defenders of these products are basically implying, if not sort of stating directly, that the pursuit of sweetness is a reasonable thing to have and that these products can deliver the sweetness that people enjoy, but potentially without negative effects. That's the position. But what about that basic proposition that the pursuit of sweetness is a reasonable thing to do, because couldn't one say that this pursuit, whether it's delivered or whether the remedy to wanting to have more sweetness comes from either sugar or artificial sweeteners, there is potential to be harmed. Wouldn't it make sense to just gradually reduce the level of sweetness in the food supply, so that people become accustomed to less sweet taste overall? I couldn't agree more with your statement. I have to say that our findings related to the non-inertness of artificial sweeteners and the potential adverse impacts on human metabolism do not imply in any form or shape that we recommend that people convert back from artificial sweetener into increased consumption of sugar. We know from endless medical literature that sugar is probably an ultimate evil when consumed in excess and is directly responsible for contribution to multiple human diseases including obesity, type II diabetes, fatty liver, and even other diseases including cancer. So going back to sugar would be a big mistake. But I totally agree with you that positioning the public opinion as one which must choose between two sweet solutions, either sugar or non-nutritive sweeteners as the only options, basically is biased because we as a post-industrial revolution human population, have dramatically increased our sugar consumption. I don't think that we need to choose between these two options. I personally opt to go back to water rather than choose between these two options which carry along probably adverse health consequences, at least in some human populations. Bio Eran Elinav is an Israeli immunologist and microbiota researcher at the Weizmann Institute of Science and the German Cancer Research Centres. He is an international scholar at the Howard Hughes Medical Institute and the Bill & Melinda Gates Foundation and a senior fellow of the Canadian Institute for Advance Research. Elinav studies the molecular basis of host-microbiota interactions, and their effects of diet, environmental factors, immune function and host genetics on the intestinal microbiome and associated multi-factorial metabolic, inflammatory malignant and neurogenerative disease. His most-cited papers have more than 2,000 cites each. Elinav developed precision microbiota interventions, including Personalized Nutrition, Precision Probiotics, small molecule ″postbiotics″, Phage Therapy, autologous fecal microbiome transplantation, Vaginal Microbiome Transplantation (VMT) and gut epithelial interventions.  

Human beings are biophotonic, plasmatic discharges and oscillating waves of energy. Some of the biggest physical ailments people suffer from can be solved by focusing on this truth, and treating the illness with what's already within.   This is where Native Phage Therapy comes in. By seeing the body as its own biocomputer, it's possible to pinpoint where the “software” is corrupted and the corrective measures that can be taken.   How does this treatment help people with infections like Lyme Disease? How do we deal with emotional frequencies trapped in the body?   In this episode, Dr. David Jernigan shares the work he's doing, and where we're headed as a species.   When you're sending a phage to fight a bacteria, it's not just going to die readily, they'll fight inside your body. -Dr. David Jernigan   Three Things We Learned    - Pull away from the convenience of pharmaceuticals Are people actually getting treated by traditional medicine or being fed a drug-induced illusion of health?   - The effect of 5G networks isn't conspiracy theory anymore What's the link between our technological quantum leaps and the massive biological dysfunction we're seeing?    - How to deal with illness Can a lot of health issues be linked to spiritual amputation and stuck energy?    Guest Bio   Dr. David Jernigan is the Founder and Owner of Biologix Center. Dr. Jernigan is one of the country's top innovators of precision bioenergetic testing and treatment technologies, with his most recent innovation, INPT (Induced Native Phage Therapy) possibly being one of his most important technologies to date. Dr. Jernigan is constantly pushing the limits of research and development with a passion to get ever closer to 100% cure rate. Dr. Jernigan was the first to publish a book on the natural treatment of people suffering from post-treatment Lyme Disease and is a published author of five books, with his best-seller being, “Beating Lyme Disease, 2nd Edition”  Dr. Jernigan is nationally recognized as a leader in the purest form of medical treatment philosophy, Biological and Bioregulatory Medicine. For 25 years Dr. Jernigan has only treated the toughest cases, with almost 90% of patients coming from other states and countries for his unique testing and treatments. He has trained doctors to utilize his powerful new technologies in his flagship clinic, the Biologix Center for Optimum Health, in Franklin, Tennessee, specializing in the treatment of chronic illness and previously considered incurable cases. He received his Bachelor's degree in Nutrition at Park University, graduating with honors, and his doctorate in Chiropractic Medicine at Cleveland University-Kansas City. He is a board-certified Doctor of Natural Medicine with an emphasis on chronic infections and chronic illness. Post-Graduate studies include natural and Anthroposophical medicine in Germany and Biological Medicine with the famed-father of European Biological Medicine, Dr. Thomas Rau, MD, of the Paracelsus Clinic of Switzerland. He is board-certified in Botanical Medicine through the University of Colorado, School of Pharmacy, and trains doctors in advanced homeopathy and bioenergetic medicine. Dr. Jernigan invented several advancements upon medical science, Biospectral Emission Sequence Testing, Matrix Interface Resonance Scanning, Fractal Frequency Modulation, NeuroPhotonic Therapy, Induced Native Phage Therapy, and NeuroCardial Synchronization. For more information, head to https://biologixcenter.com/ or call 855-955-1395.

Standardizing the phage therapy industry through processes like clinical trails is the way to go . One of the fundamental steps to broader use of phage therapy and successful therapy is producing phages following Good Manufacturing Practices (GMP) and JAFRAL is the leader in this field. In today's show we sit down with JAFRAL's founder and CEO Dr. Frenk Smrekar, a visionary who has been working on the development of GMP for bacteriophages throughout his whole career. Let's give a listen to his journey of founding the company and his observation and thought on the phage therapy field development through a GMP perspective. Learning more about JAFRAL @https://jafral.com A review paper on GMP in Phage Therapy by https://doi.org/10.3389/fmicb.2020.01161

Presenter Dr Shane is joined by Drs Jen and Euan. In this week's show the first guest, Kita Williams from QUT, talks about the environment and studying on Macquarie Island, then Graci continues her Science of Tattooing series and finally the second guest, Dr. Stephanie Lynch from Westmead Institute for Medical Research, talks about phage therapy. Then in the news Canadian fires, The Anthropause and Taurine.Remember, “Science is everywhere”, including:Program page: Einstein-A-Go-GoFacebook page: Einstein-A-Go-GoTwitter: Einstein-A-Go-Goand live every Sunday at 11:00a.m AEST on RRR 102.7mHz FM.

SpaceX Explosion Damages Environment Around Launch Site Last Thursday, SpaceX's South Texas facility was awash in noise and fire, as crowds gathered in South Padre Island and Port Isabel to watch Starship's first orbital launch. It was the largest and most powerful rocket ever made, standing at around 400 feet tall. Four minutes into the launch, SpaceX detonated the rocket after the SuperHeavy booster failed to separate from the Starship as planned. The launch destroyed the company's launch pad, spreading concrete up to three quarters of a mile away. Cameras left by YouTubers were either knocked down or destroyed in the rumble, along with some of the fence surrounding the launch pad's road-facing property. To read the rest, visit sciencefriday.com.   The Private Space Race Takes A Toll On Planet Earth After the SpaceX explosion last month, debris wasn't the only thing on the minds of Science Friday listeners. The following messages arrived in our inbox after we reported on 3-D printed rockets in March. It was interesting to hear you discuss 7 space launches in 5 days, and then just moments later the fact that we're not on track to reduce carbon emissions. My understanding is that rocket launches release huge amounts of carbon and other greenhouse gases. Story idea?—@RevBobIerien, Twitter Also regarding the 3-D rockets there wasn't any concern made for space pollution was there? I may have tuned out unhappily before the end. —Juanita H, email How much carbon do rockets contribute to global warming? —Robert C, email Very disappointing to hear the report of new “cheaper” 3D-printed rockets are available so that, like fast food pods and big gulps, we can now drop even more cheap **** into the ocean. And, *immediately* following a story about the new report on climate change, what exactly is the carbon footprint resulting from the ability of more people to more cheaply fire rockets into space? —David M, email Carbon isn't the big pollutant that comes from spaceflight, says Dr. Eloise Marais, associate professor in physical geography at University College London. Instead, black carbon or soot particles are generated and released directly into the atmosphere, alongside reactive nitrogen and nitrogen oxides. Dr. Marais joins Ira to talk about how much of an impact increased rocket launches could have on the atmosphere, and how that compares to the auto industry.    How To Combat The Antibiotic Resistance Crisis For years scientists have been ringing alarm bells about a global antibiotic resistance crisis. Now hospitals and healthcare facilities face the consequences: In the United States, there are 2.8 million antimicrobial-resistant infections every year, and more than 35,000 people die from these infections. Bacteria naturally try to outsmart the drugs designed to kill them, which causes treatments to become ineffective over time. While new antibiotics are made to respond to these resistant strains, the bacteria continue to evolve—creating a constant, and costly, cycle. There's a number of added factors driving the crisis, including antibiotic use in livestock and the general overprescription of antibiotics. About 1 in 3 antibiotic prescriptions in outpatient settings like urgent care or emergency departments are unnecessary. Scientists are struggling to keep up with the need to replace antibiotics that no longer work. It's a never ending game of catch up. Ira discusses some of the possible solutions to this vexing problem and takes listener questions with Dr. Victor Nizet, faculty lead of the Collaborative to Halt Antibiotic-Resistant Microbes at the University of California San Diego and Dr. Eddie Stenehjem, executive vice chair of medicine at the University of Colorado.   Are Phages A New Page In Medicine? One of the many possible solutions to the global antibiotic resistance crisis is an old idea that's new again—bacteriophages, or phages for short. Phages are viruses that exist solely to kill bacteria and are abundant in nature. While scientists first discovered phages' ability to treat bacterial infections about a century ago, there's been little interest in turning them into a treatment for patients with antibiotic resistant infections—until recently. Ira talks with Dr. Graham Hatfull, professor of biotechnology at the University of Pittsburgh about the latest in phage science.   Transcripts for each segment will be available the week after the show airs on sciencefriday.com.

Conor and Dodi explore the new and exciting world of bacteriophage therapy. Join them as they speak to Anton Peleg, Professor of Infectious Diseases and Microbiology and the Director of the Department of Infectious Diseases at the Alfred Hospital and Monash University, about this new, emerging field. Together they discuss how phages, viruses that specifically target bacteria, are being used to fight against antibiotic-resistant superbugs, as well as the challenges of producing them at scale and getting them approved by regulatory bodies. Tune in to Discovery Matters to learn all this and more, and join the conversation about these important advances in life sciences. Show notes For more information on Professor Anton Peleg's work with phages: Old cure revived in fight against antibiotic-resistant superbugs (smh.com.au) RNA in space: Oba, Y., Koga, T., Takano, Y. et al. Uracil in the carbonaceous asteroid (162173) Ryugu. Nature Communications 14, 1292 (2023). https://doi.org/10.1038/s41467-023-36904-3 Keywords: phage, bacteria, infection, antibiotics, rna, therapies, bacterial infections, penicillin, patients, antibiotic resistant bacteria, cholera, phage therapy, superbugs.

As the world continues to evolve toward advances in technology, the sciences, and globalization, it's important to reflect on the real-world gains of such progressions as well as the future opportunities that exist. In the case of this episode, the gains are associated with saving lives and combating the emerging threat of antimicrobial resistance and antibiotic resistant infections, which have been deemed by The World Health Organization as one of the top 10 global public health threats facing humanity. This episode is Part 2 of a series that focuses on AMR and the innovations in science and technology that are helping to tackle the challenge. The episode also points toward the connection between the issues of climate change and AMR as well as the opportunities to combine forces and develop collaborative efforts in addressing these threats. The episode digs deeper into innovations happening within healthcare to defeat superbugs as shared from the perspective of this episode's guest, Dr. Steffanie Strathdee, who is an Epidemiologist, Distinguished Professor, Global health solution-seeker, TEDx speaker, and Author of The Perfect Predator, a memoir of her effort to save her husband's life and the discovery of a forgotten cure that has the potential to save millions more. Steffanie also serves as Co-Director of the Center for Innovative Phage Applications & Therapeutics at the University of California, San Diego, School of Medicine as well as the Associate Dean of Global Health Sciences. Other topics range from the importance of advocacy and collaboration to tackle global health problems to how phages can help to evolve personalized medicine to how technologies like Machine Learning and Artificial Intelligence can be used to advance Phage Therapy. Also, is there a need for more health solutions to connect the dots when traveling abroad? For more details visit TechLink Health @ https://www.techlink.health or connect with Dr. Strathdee @ The Center for Innovative Phage Applications and Therapeutics. This episode was hosted by Rob McBride, Co-Founder and CEO of Felix Biotechnology and Dr. Sarah Samaan. The episode is packed with valuable insights and points to several references, including a direct email for those in need and interested in Phage Therapies as an alternative treatment:

In this week's Phage Therapy Today, we get back together with Dr. Gina Suh to learn about her recent progress and experience in the application of phage therapy at Mayo Clinic. If you are interested in learning about the first case of phage therapy in treatment of a cardiology case, leading to a successful heart transplant after the clearing of heavy bacterial burden, give it a listen to today's episode! Hear out about how things are progressing in the field and where are we going next from Gina's first hand experience.

We're revisiting this 2017 episode—with updates! The episode is an interview with Robert T. "Chip" Schooley, MD, a professor of medicine in the Division of Infectious Diseases and Global Public Health at the University of California, San Diego, and codirector of the school's Center for Innovative Phage Applications and Therapeutics. Dr Schooley discusses the unique events that led to the first use of intravenous phage therapy in North America. Stay tuned to the end for an update on phage therapy and on Thomas Patterson, the patient who received the lifesaving treatment. Related Content: Phage Therapy's Role in Combating Antibiotic-Resistant Pathogens As Superbugs Flourish, Bacteriophage Therapy Recaptures Researchers' Interest

Healthcare professionals are searching for new ways to fight bacterial infections as growing concerns around antibiotic resistance reach new heights. Though bacteriophages or phages—viruses that infect only bacteria—have long since captured scientists' attention, they are quickly gaining popularity as a new and promising therapeutic tool. In this episode, Graham Hatfull, professor of biological sciences at the University of Pittsburgh, speaks with host Deborah Borfitz about his team's research and diligent work to showcase phages as versatile therapeutic agents. Hatfull also talks about the impressive findings produced by experimental phage therapy clinical trials and the barriers that currently prevent phages from ubiquitous antibacterial clinical use. He discusses his team's efforts to sequence phages and build a therapeutic library, the role of phage therapy in combating tuberculosis and cystic fibrosis, and the novel benefits phages bring to transplant recipients. Hatfull also addresses the FDA's support of phage therapy through expanded access for compassionate use and the global push to enter phages into their first-ever randomized controlled trial.  Links from this episode:  Clinical Research NewzUniversity of Pittsburgh Phage Therapy of Mycobacterium Infections: Compassionate Use of Phages in 20 Patients With Drug-Resistant Mycobacterial Disease SEA-PHAGES (Science Education Alliance-Phage Hunters Advancing Genomics and Evolutionary Science) FDA Expanded Access for Compassionate Use Phage Australia 

TWiM describes successful phage therapy against a mycobacterial lung infection, and how encapsulation of the cell wall protects S. pneumoniae from its major peptidoglycan hydrolase and host defenses. Links for this episode: Phage therapy against M. abscessus lung infection (Cell) Encapsulation of the septal cell wall protects S. pneumoniae from host defenses (PLoS Path) Letters read on TWiM 279

In today's show, we sit down with Dr. Steffanie Strathdee, whose family story of saving her husband's life from a life-threatening superbug infection using phage therapy really inspired a lot of the most important works today in the phage therapy field. Listen to today's episode to learn about her story. Among her many roles, as the director of the 'Center for Innovative Phage Applications and Therapeutics' at UC San Diego, Dr. Strathdee also get to help us understand the scope of power we have today in our field and much more... Dr. Strathdee and her husband shared their story in their memoir "The Perfect Predator: A Scientists's Race to Save Her Husband from a Deadly Superbug", which can be found @ https://www.amazon.com/dp/B07H282CPT?ref=KC_GS_GB_US Their story has also recently been spread nationwide through CNN @https://www.cnn.com/2022/07/08/health/phage-superbug-killer-life-itself-wellness/index.html Find out more about UCSD IPATH and their resource @https://medschool.ucsd.edu/som/medicine/divisions/idgph/research/center-innovative-phage-applications-and-therapeutics/people/Pages/default.aspx Happy listening!

Former Detroit News reporter, Laura Varon Brown talks to The Bonnell Foundation about losing her Detroit News photojournalist husband, Jim, too cystic fibrosis.In this podcast Laura Varon Brown talks about his life, legacy and they daughter Molly they had together. The couple married in 1985, before the cystic fibrosis gene that causes cystic fibrosis was discovered by scientists in the genome project.  Jim sadly died from the disease just 5 years later, 13 weeks after their daughter Molly was born.Laura Veron Brown talks to Host Laura Bonnell about Jim's last work trip to the West Bank. Jim was there to take photographs of the armed prising of Palestinians against the Israeli occupation of the West Bank and Gaza Strip. Laura talks about being married to someone with CF, and about all the joys it brought to her life.Varon-Brown also talks about how she moved forward, remarried and had a second daughter, Emma.The two Laura's have been friends for 10 years and talk about the disease that brought them together. For more information on The Bonnell Foundation find us at:  https://thebonnellfoundation.org/Our new CF Familia page: https://thebonnellfoundation.org/familia/en-home/Thanks to our sponsors:Genentech: https://www.gene.com/Viatris:  https://www.viatris.com/enLaura Varon Brown:  https://www.gildasclubdetroit.orgThe original music in this podcast is performed by Kevin Allan, who happens to have Cystic Fibrosis.  You can find him on Facebook here: https://www.facebook.com/KevinAllanMusicThis podcast was produced by JAG in Detroit Podcasts: https://jagindetroit.com/

Dr. Steffanie Strathdee is Associate Dean of Global Health Sciences and Harold Simon Distinguished Professor in the Department of Medicine at the University of California San Diego School of Medicine. She co-directs UCSD's new center for Innovative Phage Applications and Therapeutics (IPATH), Global Health Institute and the International Core of UCSD's Center for AIDS Research. An infectious disease epidemiologist, she has spent the last two decades focusing on HIV prevention in marginalized populations and has published over 600 peer-reviewed publications. She has recently begun working to move bacteriophage therapy into clinical trials at IPATH. She has co-authored her memoir, The Perfect Predator: A Scientist's Race to Save Her Husband from a Deadly Superbug. In this podcast we talk about Dr. Strathdee's experiences learning about bacteriophage (phage) therapy treatment through a personal experience where her husband became extremely ill from antimicrobial resistant bacteria. She learned that stigma in part was how phage therapy had become forgotten in North America--stigma toward scientists with different beliefs and training than the mainstream, stigma toward viruses that maybe perceived "at the borderline of life", and stigma toward research based on geopolitics (including the "Russian taint"). Steffanie inspires listeners with her discussion of the power of global collaboration, advocacy in healthcare, and the importance of making (rather than waiting for) miracles to happen. Episode hosted by Dr. Carmen Logie. Supported by funding from the Canada Foundation for Innovation and Canada Research Chairs program. Original music and podcast produced by Jupiter Productions, who have various production services available to support your podcast needs.

Two teams are developing messages to send into space, in the hope that some advanced alien civilization will be able to pick them up. While METI is sending music, Beacon in the Galaxy is sending more complex information, like Earth's location - which as the team explains is rather controversial…Acne is usually treated using antibiotics, but as the issue of antibiotic resistance grows, researchers have been looking at alternative methods. The team discusses the promising early successes of phage therapy.Most of us overestimate just how diverse our environment is. A new study examining this ‘diversity illusion' has shown that we tend to believe minority groups are larger in number than they actually are. The team finds out how the research was carried out, and whether we can combat this bias.Known by some as the world's first computer, the Antikythera mechanism is an ancient Greek device that acts sort of like a clock. Now a group of researchers thinks they've found out the exact date and time it was calibrated to, and the team explains how they worked it out.Rhesus macaque monkeys may be as aware of their own heartbeats as human babies. The team examines a new study which looked at a kind of self awareness called interoception, the ability to detect your own internal state..On the pod are Penny Sarchet, Chelsea Whyte, Leah Crane, Jason Murugesu and Matthew Sparkes. To read about these stories and much more, subscribe at newscientist.com/podcasts.Events and discount codes:newscientist.com/pod20newscientist.com/lovenewscientist.com/courses See acast.com/privacy for privacy and opt-out information.

Dr. Sharon Stills interviews Dr. David Jernigan, innovator in Induced Native Phage Therapy and practitioner of Biological Medicine about a little known but extremely powerful method of treating disease. Did you know we have not only a microbiome, but a phageome inside each of our bodies? What is this, and what is its significance for our health?  Is it possible to reverse disease without side effects, and without waiting for years of treatment? Dr. Jernigan takes our listeners on a journey to the microscopic in an effort to cure difficult manifestations of disease.

Mallory Smiths book, Salt in my Soul was published posthumously by her mother, Diane Shader Smith (husband Mark) after she died from CF at the age of 25 years old.  Smith died after a double lung transplant.  So many people have read her book.  I bought it years ago, but was never able to read it.  I have a mental block, lots of CF books sitting on my shelf that I can't read.  I am living this life, I am raising not one but two girls with cystic fibrosis.  I didn't think I could handle any of these books, but I bought them, and they sat on my shelf. Serendipity happened to me, as it always does with CF related incidents. I was on a  zoom webinar, got bored, and started looking at their Ads.  One popped out at me:  Lost Women of Science with NY Times reporter Katie Hafner. She did a four part series about Dr. Dorothy Anderson, who discovered in 1938, that CF existed.  So for whatever reason, it seemed time  to start reading all these books I had -- with my girls at 27 and 24 years old, it was time to delve into everything CF. At this time Diane Shader Smith and Director, Will Battersby were debuting their film, Salt in my Soul.  It was Mallory's story on film.  It featured her videos, writings, her story.  I didn't know what to expect, but after watching it I felt like Diane was my CF Mom Soulmate and I had to talk to her.  That's where our story begins.In this podcast you'll hear from Diane and Will.  We talked about everything from Phage therapy that could have saved Mallory, to staying strong and pushing for more in the world of CF.  Will Battersby: @Battersby4WillFilm link: saltinmysouldoc.comDiane Shader Smith: @dianeshadersmthTrailer link: https://youtu.be/m5779DFldHAFilm: @SaltInMySoulDocMore on phage therapy: @YalePhageSalt in My Soul Website: https://saltinmysouldoc.com/ 

Why You Should Listen:  In this episode, you will learn about the use of Induced Native Phage Therapy in dealing with chronic infections. About My Guest: My guest for this episode is Dr. David Jernigan.  David Jernigan, DNM, DC is one of the country's top innovators of precision bioenergetic testing and treatment technologies, with his most recent innovation, INPT (Induced Native Phage Therapy) possibly being one of his most important technologies to date.  He is constantly pushing the limits of research and development with a passion to get ever closer to 100% cure rate.  He was the first to publish a book on the natural treatment of people suffering from post-treatment Lyme Disease and is a published author of five books, with his best-seller being, “Beating Lyme Disease, 2nd Edition”.  He is nationally recognized as a leader in the purest form of medical treatment philosophy, Biological and Bioregulatory Medicine.  For 27 years, Dr. Jernigan and his team of doctors have only treated the toughest cases, with almost 90% of patients coming from other states and countries for his unique testing and treatments.  He has trained doctors to utilize his powerful new technologies in his flagship clinic, the Biologix Center for Optimum Health, in Franklin, Tennessee, specializing in the treatment of chronic illness and previously considered incurable cases. Key Takeaways: What are phages and where do they originate? How difficult is it to find phages in our environment? Are phages always health-promoting? How does a phage lead to the demise of an organism? Does each bacteria or bacterial species have its own phage? How does INPT induce native phages? Can multiple phages be induced simultaneously? Does INPT lead to Herxheimer reactions? What was the success rate with INPT in a recent research paper? Do lab tests exist for Borrelia phages? Bartonella?  Others? Can phages be used to address fungal colonization from exposure to water-damaged buildings? Are phages helpful in addressing Candida overgrowth? Might a phage be helpful in addressing MARCoNS? Do phages work for parasites? Can phages deal with viruses such as EBV or Herpes Zoster? Does the right phage for the triggering infection bring resolution to conditions believed to be autoimmune? Connect With My Guest: http://BiologixCenter.com http://PhagenCorp.com Related Resources: Research Paper: Induced Native Phage Therapy for the Treatment of Lyme Disease and Relapsing Fever: A Retrospective Review of First 14 Months in One Clinic Interview Date: March 10, 2022 Transcript: To review a transcript of this show, visit https://BetterHealthGuy.com/Episode161. Additional Information: To learn more, visit https://BetterHealthGuy.com. Disclaimer:  The content of this show is for informational purposes only and is not intended to diagnose, treat, or cure any illness or medical condition. Nothing in today's discussion is meant to serve as medical advice or as information to facilitate self-treatment. As always, please discuss any potential health-related decisions with your own personal medical authority. 

There have been several quite famous successful cases of using phage therapy for treatment. One of those cases was carried out at Mayo Clinic by the founder and director of Mayo Clinic's Phage Therapy Program Dr. Gina Suh. Listen to our conversation on this story and the consideration along the process. We dig deep into how physicians are perceiving phage therapy and where we will go from there. Check out Dr. Suh's recent publication 'Considerations for the Use of Phage Therapy in Clinical Practice' :https://pubmed.ncbi.nlm.nih.gov/35041506/

We're being told we have to “learn to live with covid”, but what exactly does that mean? In this episode the team discusses how we live with flu and the measures we'll need to take to prevent wave upon wave of covid-19 infections and deaths. There's been a massive volcanic eruption in Tonga that's caused widespread damage, and the team examines the impact it's having on the island nation. There's more news in the race to build the world's best quantum computer - the team finds out about a unique way of building these machines using neutral atoms. As antibiotic resistance continues to cause deaths worldwide, an alternate therapy using phages is growing in popularity - the team finds out about the pros and cons of this type of treatment. And the anthropologist Beth Singler joins the conversation - she looks specifically at human interactions with artificial intelligence, in an attempt to understand our fear of and reverence for the technology. On the pod are Penny Sarchet, Sam Wong, Michael Le Page, Alice Klein, Emily Bates and Alex Wilkins. To read about these stories and much more, subscribe at newscientist.com/podcasts. Thanks to our sponsor Brilliant - remember the first 200 people to sign up using this link http://brilliant.org/newscientist will get 20% off unlimited access to all the courses on Brilliant for a whole year. To book a ticket for our New Scientist live event ‘Understanding The AI Revolution', click here. And for tickets to see professor of psychiatry Ted Dinan live as part of our health and wellbeing online events series, click here. See acast.com/privacy for privacy and opt-out information.

Welcome back to Phage Therapy Today and in this episode, we have Dr. Minmin Yen from PhagePro joining us to discuss her and her team's recent progress on bringing preventive phage therapy product to fight Cholera, an acute, diarrheal illness that's often associated with poverty, poor infrastructure and social injustice. Listen to her journey of bringing her research to entrepreneur execution and how our phage therapy community has been involved. Find out more about PhagePro at: https://www.phageproinc.com/

Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator(CARB-X) is one global nonprofit partnership that manages a large portfolio of early stage companies to do the job as described by its name. In this episode, we are happy to have its chief scientist Dr. Richard Alm to help us paint a broad picture of the antimicrobial landscape and discuss their investment strategies related to phage therapy. The global biotech is a $800B dollar market this year, with a >15% CAGR, what can we do to promote the scientific understanding of phage and phage therapy in this capital driven economy? Find out more about CARB-X at their website: https://carb-x.org

Dr. Irene Chen is currently a faculty member at UCLA working on building the next generation phage therapy platform. If you are new to this field and want to catch up a bit, this is the right episode for you. On this episode, we'll talk about what phages are, what phage therapy is, what's the current state of art and much more. Besides the amazing science and technology phages are providing us, let's envision what really does phage therapy mean for our society. Yes, some of these stuff, you can learn about just from the other 10 podcast episodes on phage out there but it's simply better here.

We may think the magic in phage therapy is in the treatment. That is true. But to make this magic happen, collaborative team efforts is necessary to  together prepare the stage and get ready for the show. Dr. Sabrina Green is currently the director of R&D at Baylor college of medicine Tailorlabs 'https://www.bcm.edu/research/research-centers/tailor'. On this episode, we sit down and truly understand the steps required to develop a phage product and supply it to the patients. Happy Listening!

To claim credit for this episode, visit: Mayo Clinic Talks Podcast: Genes & Your Health Guests: Gina A. Suh, M.D. Host: Denise M. Dupras, M.D., Ph.D. What is Phage Therapy? When was it discovered? Where is it used? We know about antibiotics, antifungals, and antivirals, but this is a whole new world! Have no fear, this episode is here from the Genes & Your Health miniseries to help demystify all there is to know about Phages. Connect with the Mayo Clinic's School of Continuous Professional Development online at https://ce.mayo.edu/ or on Twitter @MayoMedEd.  

Phage therapy today is the go to podcast to learn about current achievement and progress in phage therapy. We've gathered incredible guests joining us to share their works and ideas using phage therapy to fight this antimicrobial war. We do this together, and together we can do this.

29 October 2021 - EMBO Member Adriano Aguzzi is the Director of the Institute of Neuropathology at the University of Zurich. The Aguzzi lab investigates the molecular basis of prion diseases and other neurodegenerative illnesses. We spoke with Adriano Aguzzi and Review Commons project leader Thomas Lemberger about preprints, peer review, paying for innovation in publishing, and an unexpected positive control.

22. October 2021 - Pediatric infectious disease physician Dr. Ameneh Khatami, senior author Dr. Jonathan Iredell and their collaborators recently published in EMBO Molecular Medicine the story of a seven-year-old girl infected with a multi-drug resistant Pseudomonas strain. The team resorted to an experimental treatment with a long history, phage therapy. In this episode of the EMBO Podcast, Dr. Khatami told us the story of her young patient. We'll also stop briefly at Stalingrad, hear about a very sick sea turtle, and discuss the challenges of interpreting single-patient studies. Note: We'd like to thank Dr. Dmitriy Myelnikov (University of Manchester) and Dr. Jessica Sacher (Phage Directory) for their participation in this episode. Sound mixing: 366 Ideias/Marco Antonio

phage therapy: nature's “antibiotics”. could it be an alternative treatment against antibiotic resistance or is it just too risky with the limited amount of research?

Imagine the last time you were sick and needed antibiotics...now imagine that you took the antibiotic, but the infection didn't go away. The antibiotic didn't work. And then the next one didn't. And then the next one, all the way until none of them worked.It happens. And although I've never personally experienced this, I'd think it would be terrifying.What would you do? Recently, some doctors have started using viruses called bacteriophages (or phages for short) that can kill bacteria. It's called phage therapy, and it's saving people's lives. In the US, phage therapy is something doctors can access only through special authorization by the FDA. But it's gaining popularity. And in some countries, phage therapy is actually the preferred treatment of choice, but we'll get to that later.So, on this podcast episode, I talk to Dr. Jessica Sacher, who is the co-founder of Phage Directory, an organization that connects doctors and patients to scientists that work with phages. Phage Directory simplifies the process of finding the treatment patients desperately need for bacterial infections that have stopped responding to antibiotics. When the antibiotics stop working, phages can cure superbug infections.In this episode, you will learn about…An introduction to virusesPhages: viruses that infect bacteriaHow to see virusesMost viruses do not make us sickCould phages ever make us sick?What makes phages so specific to the bacteria they infect?What is phage therapy?Phage Directory: connecting doctors and patients to scientists with phagesAt-home microbiology activity: Fishing with phagesJOYFUL MICROBE SHOW NOTES: https://joyfulmicrobe.com/phage-therapy-jessica-sacher/JOYFUL MICROBE NEWSLETTER: https://joyfulmicrobe.com/newsletter/JOYFUL MICROBE TWITTER: https://twitter.com/joyfulmicrobe/JOYFUL MICROBE INSTAGRAM: https://www.instagram.com/justineldees/

Joining us today is Dr. Richard Allen White III from the University of North Carolina Charlotte. We talk about virology, the evolution of life on Earth, phage therapy, and Richard also talks about his startup Raw Molecular Systems Inc.    We really enjoyed our conversation with him and hope to have him again in the future.   You can find us on Twitter at @MicrobiGals or on our website at microbigals.com where we are updating with new content, including blog posts, regularly.   Also, if you would like to donate to our show, we have started a kofi page. you can donate on our website or visit https://ko-fi.com/microbigals

Phages or bacteriophages are bacterial viruses that can kill antibiotic-resistant bacteria. The use of phages to treat infections is called phage therapy. In this episode, Dr. Anthony Maresso an Assistant Professor in the Department of Molecular Virology and Microbiology and expert in bacterial pathogenesis will be discussing the work being done at Baylor to develop phage therapy for the most vulnerable patients. As well as his partnership with Dr. Barbara Trautner an infectious disease clinician and researcher at BCM and the Michael E. DeBakey Veterans Affairs Medical Center. She will be discussing her research into phage use for catheter-associated urinary tract infections. They will give their insight into the use of phages to combat the epidemic of antibiotic-resistant bacterial infections today.

Devouring Bacteria: How Phage Therapy Is Shaping Antibacterial Treatments of the Future In this episode we speak with the CEO of BiomX, Jonathan Solomon, about producing and using phages to test and treat various diseases and conditions. Until very recently, treating a condition such as acne with an army of microscopic bacteria-destroyers known as phages—bacterial viruses that target and kill specific bacteria—would have seemed highly unlikely. However new research linking acne to an imbalance in the skin’s microbiome has opened the door to innovative treatment approaches. That’s where the biotech company BiomX comes in. Uniting powerful computational science with the inherent capacity of phages to destroy specific bacteria, BiomX creates natural and synthetic phage therapies for some of the most troublesome bacteria-related health issues: acne, atopic dermatitis, cystic fibrosis, inflammatory bowel disease (IBD) and even colorectal cancer. For acne the company has developed a successful cocktail of three different phages to treat the condition, with phase 2 testing close on the horizon. BiomX’s developments in phage therapy promise to change the way we treat imbalances in our microbiome, with potential health benefits for large swaths of the population. Curious to Know More? To learn more about BiomX, listen to the conversation with Jonathan Solomon on this episode of A View On: Phage Therapy. KEY TERMS: Bacteriophage (also known as a phage): A virus that attacks and devours only bacteria (‘phagein’ in Ancient Greek means to devour). Bacteriophages are bacteria-specific, which is both an advantage and disadvantage in manufacturing treatments. Fun fact: taken altogether, bacteriophages are the most numerous entity on the planet. Phage cocktail: Since a phage targets and destroys only one type of bacteria, treatments for complex ailments necessitate a mixture, or cocktail, of different phages to be effective. Phage fermentation: Although destructive, unwanted phages can grow during fermentation processes for wine-making and milk production, fermentation is nevertheless the optimal way to produce phages for therapeutic uses. Computational (science): Computer modelling of the phage and its potential interaction with specific bacteria (known as in silico testing) allows researchers to develop phage cocktails more efficiently and with a greater chance of success.

"This is the worse superbug you can get," said her husband's doctors when diagnosing him with a life-threatening multidrug resistant bacterial infection.  But Steffanie Strathdee put her research skills to work and eventually was able to convince doctors to treat him with an experimental phage therapy that ended up saving his life. Listen and learn Why no other solution was working to cure her husband of this superbug, How the history of phage therapy versus antibiotics has played out, and Why the problem of antibiotic resistance may be addressed by utilizing bacteriophages. Steffanie A. Strathdee is the Associate Dean of Global Health Sciences and the Harold Simon Professor in the Department of Medicine at the University of California San Diego School of Medicine. She helped found and co-directs UCSD's new center for Innovative Phage Applications and Therapeutics (IPATH) and also works with the Global Health Institute and the International Core of UCSD's Center for AIDS Research.  An infectious disease epidemiologist, she's also the author of The Perfect Predator, which tells the story of her husband's struggle with a superbug and the successful effort to help him recover with phage viruses. Phages are viruses that infect bacteria, and are emerging as a potential winner as scientists struggle with how to prevent superbugs from causing deadly infections.  She gives listeners a fascinating history of how politics and war kept phage therapy out of American medicine for decades. First discovered by a French Canadian microbiologist, their adoption by Russians pre-World War II marked them as off-the-table for the American medical field. But they are emerging again as having great potential, and Steffanie Strathdee helps enlighten listeners by describing the process and why they can be effective. First, scientists are able to pick and choose their phages, testing to make sure what bacteria the phages will infect. They can get specific, killing only the bacteria they want to target. Ideally, they'll collect a couple of different phages for the best chances of success, then make isolates of them.  The most difficult stage is the purification, she says. Scientists are moving ahead, designing clinical studies. Listen in for more exciting news about this life-saving treatment. For more, see the Innovative Phage Applications and Therapeutics (IPATH) website. Available on Apple Podcasts: apple.co/2Os0myK

This podcast explores how one researcher is working to keep babies safer without turning to antibiotics. Group B Streptococcus (GBS) presence in the mother is a leading cause of neonatal morbidity and mortality. Doctors often treat mothers with antibiotics to curb the infection, which presents its own complications. Richard interviews a microbiologist working on alternatives. Listen and learn How GBS transmission happens and what screening processed is used, What different strains of GBS exist and are they equally infectious, and How phage therapy may be the best solution to decrease infection rates while leaving the microbiome of the baby balanced and healthy. In this episode, Richard speaks with a researcher specializing in perinatal microbiology and infections of the perinatal period. She examines how these infections can modify the outcome for mothers and babies. By looking at the epidemiology and how GBS strains change regarding capsule type and other factors in different regions, she hopes to learn more about the bacteria to utilize a bacteriophage for infecting the bacteria. What's a bacteriophage versus a virus? One way to understand the difference is to consider the host: bacteriophages are viruses that infect bacteria. The bacteriophage life cycle is intertwined with the host bacteria, and many researchers are looking at bacteriophages in the human body as a treatment alternative to antibiotics.  Because antibiotics are used to treat bacterial versus viral infections and can kill beneficial organisms inhabiting the baby, phage therapy may benefit babies in multiple ways. GBS transmission occurs during the vaginal birth process if the mother has the bacteria. While some babies can remain healthy despite this, others are infected with harmful results including death. Therefore, widespread screening is in place, testing the mother. Generally a mother is given antibiotics a few hour before labor. This microbiologist is researching candidate phages for therapy and also trying to understand more about natural exposure to phages during pregnancy. Listen in for more about this dynamic and potentially life-saving work. Available on Apple Podcasts: apple.co/2Os0myK

This interview explains Biologix proprietary phage therapy that is showing success clearing Persistent Lyme Disease, or PLD and coinfections in a gentle way, even for the most sensitive of patients 45 days after treatment.  Kristina discusses with Dr. Hart what a potential patient might expect from treatment at Biologix and why phage therapy.  It does not treat known illnesses, rather supports the body in being able to do the work by providing the phages specific to each strain a patient presents.Phage is a holistic treatment that has the potential of supporting the body to clear a multitude of pathogens such as Lyme, cancer, COVID, viruses, parasites, and persisters.  A clinical study is underway to show the results of 30 patients.  It will be shared on Facebook @ Texas Lyme Alliance, Twitter @TexasLyme on online at www.TexasLymeAlliance.org.Did you know that your immune system should not be made solely responsible for killing the infections in your body? Phages—or viruses that do not infect human cells—are well-known entities whose sole purpose is to swarm host microbes and replicate themselves in order to attack and kill them. Using Induced Native Phage Therapy, we at the Biologix Center have discovered exactly how to access the bacteriophages (phages that attack bacteria), mycophages (phages that attack mold and fungi), and virophages (phages that attack other viruses) that already reside inside your body and induce them to eliminate, in most cases, all infectious microbes wreaking havoc there.**This is not medical advice.  Kristina Bauer has no conflicts of interest and is not paid for services.  Texas Lyme Alliance supports this work and also does not receive payment for services from Biologix or any of its entities.  Kristina or Texas Lyme Alliance's effort is to support patients through the sharing of information and education and does not recommend any treatment.  We want patients to heal, stay out of bed, and get back to life at work and in their families.For more information, contact the Biologix Center at www.BiologixCenter.com.  Subscribe for future educational videos on healing Lyme Disease by clicking the subscribe button and sharing this video.  Thanks for watching and good luck!Support the show

Alternative strategies are needed to combat and prevent antibiotic-resistant bacterial infections. Host Ashish K. Khanna, MD, FCCP, FCCM, talks with David R. Cameron, PhD, about the potential for bacteriophage prophylaxis in the context of experimental ventilator-associated pneumonia due to methicillin-resistant Staphylococcus aureus in rats.

Alternative strategies are needed to combat and prevent antibiotic-resistant bacterial infections. Host Ashish K. Khanna, MD, FCCP, FCCM, talks with David R. Cameron, PhD, about the potential for bacteriophage prophylaxis in the context of experimental ventilator-associated pneumonia due to methicillin-resistant Staphylococcus aureus in rats.

Bacteriophages have long been used to treat infections. These naturally occurring virus are capable of killing bacteria, but each strain of phage is highly specific. Because of their unique mechanism of action, they provide a potential to address the growing threat posed by multidrug-resistant bacteria, but to treat someone, the right phage must be matched to each patient's infection. Adaptive Phage Therapeutics believes it's found a way to create phage therapies suited to treat patients with drug-resistant infections by building a bank of targeted and genomically-screened bacteriophage and testing individual patient's bacterial colony against that to determine the appropriate phage to treat them. We spoke to Greg Merril, co-founder and CEO of Adaptive Phage Therapeutics, about the origins of the company, how its technology works, and the regulatory hurdles for producing customized therapies to treat individual patients.

"Never Give Up on Your Life" - John Haverty. John Haverty is a chef, a family man, a patient who was battling a stubborn bacterial infection in his leg for over 10 years. He wasn’t able to walk and put both feet on the ground for over 10 year. Doctors at Mayo Clinic were about to amputate John's leg as the last resort until a virus (called Phage Therapy) saved his life. Antibiotic resistance is now a public health crisis because we have these ’smart bacterial bug’ that can change and develop the ability to defeat the drugs that were designed to kill them. If you believe in miracle and want to believe in miracle, then this episode is for you and your loved one, who may be at struggling to find success with conventional Western Medicine and are considering to explore experimental therapy. Why is Antibiotic resistance is a serious public health issue? The causes of antibiotic resistance are due to many reasons such as: 1. Over-prescription of antibiotics 2. Patients not finishing the entire antibiotic course 3. Overuse of antibiotics in livestock and fish farming 4. Poor infection control in health care settings 5. Poor hygiene and sanitation 6. Absence of new antibiotics being discovered This episode will cover: 1. How John almost gave up on his leg until a supportive loved one helped him to find the courage to fight the last fight 2. What is phage therapy using Adaptive Phage Therapeutics 3. How can patient apply for the use of experimental therapy through the "compassion use clause with the Federal Drug and Administration (FDA)" 4 How phage therapy is administered in the clinic 5. What is the cost of phage therapy 6. How to advocate for your own life, because no one else will. Resources: 1. Connect with John Haverty by email at Chefjmh57@gmail.com 2. Learn more about the Adaptive Phage Therapeutics, a clinical-stage company founded to provide an effective therapy to global rise of multi-drug resistance pathogenic bacteria at http://www.aphage.com 3. Learn more about the research on phage therapy at University of California, San Diego (UCSD) https://medschool.ucsd.edu/som/medicine/divisions/idgph/research/center-innovative-phage-applications-and-therapeutics/Pages/default.aspx 4. Check out the book "The Perfect Predator: A Scientist's Race to Save Her Husband from a Deadly Superbug: A Memoir", by Stephanie Strathdee and Thomas Patterson 5. Connect with others on Facebook Group: Phage Page If you are interested in being a part of the invisible force called "Public Health" by sharing your story, please connect with the host, Dr. Kee Chan. Connect with on Linkedin http://www.linkedin.com/in/keechan and by email at keechanphd@gmail.com. --- Send in a voice message: https://anchor.fm/whatispublichealth/message Support this podcast: https://anchor.fm/whatispublichealth/support

What is phage therapy?Phage therapy refers to the use of bacteriophages to treat bacterial infections. While it has been used scarcely in the Western world in recent decades, some doctors and researchers see a need for it in the future, to combat antibiotic resistance among bacteria.In 1917, French-Canadian microbiologist Félix d’Hérellee discovered phage therapy. Bacteriophages, or phages for short, are actually viruses which are extremely common in the biosphere. They’re able to kill bacteria by invading them and multiplying within them. Phage therapy can be used to treat basic wounds, as well as different kinds of bacterial infection, like bone infection, respiratory infections and MRSA. Instead of using antibiotics, which destroy all bacteria they come across, specific strains or cocktails of phages are used for each patient. At the time antibiotics were created, public authorities considered them more simple and effective than phages. To such an extent that phages were gradually forgotten and even destroyed in many countries.But in the 21st century, certain bacteria have become resistant to antibiotics, which is a major health issue. Researchers have renewed their interest in phages and are looking at their potential uses to fight otherwise incurable diseases.Some countries actually already use phage therapy, most notably in Georgia. Sick patients from around the world are spending thousands of dollars to travel to Tblisi, the country’s capital. They then spend several weeks undergoing treatment at the Eliava Institute. See acast.com/privacy for privacy and opt-out information.

What is antibiotic resistance? How is it spread? Are there alternatives to antibiotics? Join the FMM team and find out the answers to these questions and much more!

On this episode, we are taking a closer look at the extremely real, human threat of antibiotic resistant infections, and discussing how momentum for beating these harmful bugs can start from just one person with a determination to find a solution. Co-host Matthew Wellington from U.S. PIRG interviewed Dr. Steffanie Strathdee, co-author of the book The Perfect Predator - A Scientist’s Race to Save Her Husband from a Deadly Superbug. Dr. Strathdee is the Associate Dean of Global Health Sciences, Harold Simon Professor at the University of California San Diego School (UCSD) of Medicine and Co-Director at the Center for Innovative Phage Applications and Therapeutics. In this episode, she tells the story of how her husband, Tom Patterson, was infected with a bacteria that was resistant to all available antibiotics and how doctors and researchers from around the world saved his life with a hundred year old forgotten cure—phage therapy—that shows promise as a weapon to tackle the global superbug crisis. Her husband co-authored the book with her and is also a renowned scientist at UCSD. To wrap up, Matt will dive into the news and updates currently chiming across the world of antibiotic resistance.

This is a type of therapy that kills pathogenic bacteria that cause cancer and disease and was discovered circa 1890s. Here are some links:www.eliava-instutute.orgMusic by Twisteriumlicensed to Linda Manuel thru Audio Jungle May 2019For show ideas email lindamanuel.44425@gmail.comwww.lindaemmanuel.com

A treatment from World War I is making a comeback in the struggle to beat deadly multidrug-resistant infections." By Charles Schmidt.

A treatment from World War I is making a comeback in the struggle to beat deadly multidrug-resistant infections." By Charles Schmidt.

The microbio gang is growin’ (exponentially): Emily Kang, from San Diego, sunny California, won second prize Grand award in microbiology at Intel ISEF 2019. Her project is called: Turning Over a New Phage (that pun though): A Novel Approach to Phage Therapy. Her approach minimizes the potential for resistance in bacteria. She’s also involved in synthetic biology; Emily is going to the iGEM competition hosted by MIT this fall. Her group is using E.coli to degrade toxic compounds in crude oil. Let’s take a few moments of science! The STEM shoutout goes to a non-profit organization, STEAM for all. They “strive to provide meaningful community service opportunities, develop leaders through student-led service activities, and promote STEAM education globally”. I had Pranav Moudgalya, board member on the pod expanding on the work they do and how you can be part of that impactful organization! Check out www.steamforall.org

Absolute honour to have Dr. Steffanie Strathdee as my guest for episode 19. Dr. Strathdee is an infectious disease epidemiologist, Associate Dean of Global Health Sciences, Harold Simon Professor at the University of California San Diego School of Medicine and Co-Director at the Center for Innovative Phage Applications and Therapeutics. Herself and husband; Thomas Patterson, are also authors of the book 'The Perfect Predator: A Scientist's Race to Save Her Husband from a Deadly Superbug'.On the podcast we talk about Phage Therapy, what it is and the difference it can make in the Superbug Epidemic, the struggle Dr. Strathdee and her husband faced, recovery and everything that happened in between. I really hope you find it as fascinating and important as I did. Follow Dr. Strathdee on:Twitter - https://twitter.com/chngin_the_wrldInstagram - https://www.instagram.com/chngin_the_wrldCheck out Dr. Strathdee's University Profile here: https://profiles.ucsd.edu/steffanie.strathdeeFor more information on 'The Perfect Predator' head here: https://theperfectpredator.comPurchase the book: https://amzn.to/2Q50tnPFind out more about IPATH (Center for Innovative Phage Applications and Therapeutics):Website: https://bit.ly/2kGpg2HFacebook: https://www.facebook.com/IPATH/Twitter: https://twitter.com/IPATHContact IPATH: IPATH@ucsd.eduMake sure to give us a follow and give this episode a share, it helps the world and this is a topic which completely deserves it! Support the show (https://ko-fi.com/miztrujillo)

Bacteriophages (“phages”), or bacterial viruses, are the most abundant biological entity on the planet, and the microbial world is shaped by these predators and parasites. The ability of bacteriophages to specifically target and kill their prey is being explored as an alternate therapy to antibiotics against various bacterial diseases. Dr. Graham Hatfull is a professor at the University of Pittsburgh who studies Mycobacterium tuberculosis, the causative agent of tuberculosis, and the phages that infect it. Hatfull directs the Science Education Alliance-Phage Hunters Advancing Genomics and Evolutionary Science (SEA-PHAGES) program along with the Howard Hughes Medical Institute. Hatfull talks about how the SEA-PHAGES program has allowed entering students at more than 100 colleges and universities around the country to discover thousands of new phages, how phages isolated from the program were used to save the life of a patient infected with Mycobacterium, what the prospects are for phage therapy being used as treatment for other diseases, how bacterial resistance to phage infection impacts phage therapy, and how important research experience can be for students. microTalk was joined by Dr. Jimmy Ballard when this podcast was recorded at the ASM Microbe 2019 conference in San Francisco, CA. The microCase for listeners to solve is about Buck Shott, an aging Western movie stunt double who comes down with a potentially fatal infection after filming an action scene for “The Old, the Ancient, and the Geriatric”. Participants: Karl Klose, Ph.D. (UTSA) Graham Hatfull, Ph.D. (University of Pittsburgh) Jimmy Ballard, Ph.D. (University of Oklahoma) Janakiram Seshu, Ph.D. (UTSA) Mylea Echazarreta (UTSA)

Wheeler, Ollie and Lekter talk about this year's Win Your Space YK winner - the Fat Fish - as well as making some likely uninformed inquiries about one of the contest runner-ups, Phage Therapy. And when you're at a live auction for a classic Porsche and you're already bidding in the tens of millions of dollars, what's a few million more?

Show notes: In the show, The Bio Busters professors, Dr. A and Dr. C, discuss phages, their life cycles, applications (both industrial and therapeutic), potential drawbacks, and future directions. Keep the discussion and comments going on the iTunes review section, or feel free to e-mail the podcast with future show ideas and thoughts on the current show. Music by Bahaa Naamani Email us at thebiobusters@gmail.com References: Cell Host Microbe. 2019 Feb 13;25(2):219-232. doi: 10.1016/j.chom.2019.01.014. Phage Therapy: A Renewed Approach to Combat Antibiotic-Resistant Bacteria. Kortright KE1, Chan BK2, Koff JL3, Turner PE4. Science. 2019 Mar 29;363(6434). pii: eaat9691. doi: 10.1126/science.aat9691. Bacteriophage trigger antiviral immunity and prevent clearance of bacterial infection. Sweere JM1,2, Van Belleghem JD1, Ishak H1,3, Bach MS1, Popescu M1,2, Sunkari V1, Kaber G1, Manasherob R1, Suh GA1, Cao X1, de Vries CR1, Lam DN1, Marshall PL1,2, Birukova M1,2, Katznelson E1, Lazzareschi DV1, Balaji S4, Keswani SG4, Hawn TR5, Secor PR6, Bollyky PL7.   Viruses. 2018 Apr; 10(4): 205. Published online 2018 Apr 19. doi: 10.3390/v10040205 Bacteriophage Applications for Food Production and Processing Zachary D. Moye,* Joelle Woolston, and Alexander Sulakvelidze https://www.sciencedaily.com/terms/antibiotic_resistance.htm https://www.forbes.com/sites/quora/2018/03/28/why-bacteriophage-therapy-wont-solve-the-problem-of-antibiotic-resistance/#5c26f92fbf3f

Bacteriophage are viruses that infect specific bacteria. Jeremy Barr discusses his discovery that phage interact with (but don’t infect) mammalian epithelial cells. He explains how these different organisms: bacteria, bacteriophage, and the mammalian host, may exist in three-way symbioses. Subscribe (free) on Apple Podcasts, Google Podcasts, Android, RSS, or by email. Also available on the ASM Podcast Network app. Julie’s Biggest Takeaways Jeremy’s work as a postdoc focused on developing a protocol to clean phages for use in tissue culture. He and his advisor, Forest Rohwer, were asked to use this protocol to clean phages for a patient extremely sick with a multidrug-resistant Acinetobacter baumannii isolate. Within 24 hours, they used an experimental lab method to clean and purify phages that were used in an experimental procedure to treat a very sick person; phage therapy ultimately saved his life. Jeremy discovered that phages can pass through human epithelial cells by using a transwell system. Phage interaction with epithelial cells is not the same as an infection, since the phages cannot use mammalian molecular machinery to reproduce. Jeremy hypothesizes that the epithelial cells take up phage during active sampling from the gut, during which epithelial cells sample the environment to inform the immune system. Jeremy’s work is building toward a model of tripartite symbioses. This includes symbiosis between bacteria and mammalian cells, between bacteria and bacteriophage, and between bacteriophage and mammalian cells. Bacteria can interact with mammalian cells to influence host cell signaling to their benefit, and Jeremy’s hypothesis is that phage will be found to do the same.  Building a gut-on-a-chip allowed Jeremy to study the interactions of phage with the gut in a controlled environment. The preliminary results suggest that the phage adapt to better adhere to the mucosal surfaces over time. Discovering the protein domains that phage use to stick to mucins opens up the possibility of using these domains in personalized therapeutics, by designing these into new phage or other therapeutics.  Jeremy’s 2 major pieces of advice for early career scientists: Follow what excites you! Find an aspect of biology that you're really passionate about and follow that.  Find amazing mentors. Contact even people you don’t directly work with, reach out to them and build your network. Links for This Episode MTM Listener Survey, only takes 3 minutes. Thanks! Jeremy Barr lab website The Perfect Predator by Steffanie Strathdee Gordillo Altamirano FL and Barr JJ. Phage Therapy in the Postantibiotic Era. Clin Microbiol Rev 2019.  Nguyen S. et al. Bacteriophage Transcytosis Provides a Mechanism to Cross Epithelial Cell Layers. mBio 2017.  Microbe information

One more month at the AMR Studio, we bring you a heartwarming conversation around AMR experiences and work. This month we feature an interview we did with Gerry Wright, a biochemist turn microbiologist working on drug development,and that personally had to face the reality of AMR. In our news section we bring you the happy story of a cystic fibrosis patient successfully treated using phage therapy, and the recent news about an emergent resistant fungal infection. Check relevant links and material at www.uac.uu.se/the-amr-studio/episode8/. Follow our updates on twitter on www.twitter.com/uac_uu with #theAMRstudio hashtag! Theme music by Henrik Niss: www.tinyurl.com/henriknissspotify.

In Part 2 of our "Salt In The Soul" series.  Paige and Martha are joined by Mallory Smith's father, Mark Smith.  Mark educates us about Phage Therapy. Phage therapy is widely being reconsidered as an alternative to antibiotics. The use of naturally-occurring phages to treat bacterial infection has a contentious history in western medicine.  Mark discusses all the research and treatments he looked into while trying to help his daughter, Mallory.  To donate to Mallory's Legacy Fund CLICK HERE  Purchase Mallory's Book "Salt in My Soul: An Unfinished Life"

Steffanie A. Strathdee is the associate dean of global health science at the University of California San Diego School of Medicine and Co-Director at the Center for Innovative Phage Applications and Therapeutics. She is known for her work on HIV research and prevention programmes in Tijuana.  

A Canadian infectious disease epidemiologist, Steffanie Strathdee turned to a very old, and experimental treatment option after her husband, Thomas Patterson, contracted a superbug while they were travelling in Egypt in 2015. She looked into something called “Phage Therapy” (using an infection to fight an infection).

Delve into the realms of predatory superbugs with infectious disease epidemiologist Steffanie Strathdee and her husband, psychologist Thomas Patterson. This is an incredible story of Strathdee’s fight to save her husband’s life, which led her to rediscover a forgotten treatment for antibiotic-resistant bacteria. This unprecedented treatment saved Patterson’s life as well as several others and helped launch the Center for Innovative Phage Applications and Therapeutics (IPATH) at UC San Diego, the first phage therapy center in North America. Series: "Women in Science" [Health and Medicine] [Show ID: 34410]

Delve into the realms of predatory superbugs with infectious disease epidemiologist Steffanie Strathdee and her husband, psychologist Thomas Patterson. This is an incredible story of Strathdee's fight to save her husband's life, which led her to rediscover a forgotten treatment for antibiotic-resistant bacteria. This unprecedented treatment saved Patterson's life as well as several others and helped launch the Center for Innovative Phage Applications and Therapeutics (IPATH) at UC San Diego, the first phage therapy center in North America. Series: "Women in Science" [Health and Medicine] [Humanities] [Show ID: 34410]

Delve into the realms of predatory superbugs with infectious disease epidemiologist Steffanie Strathdee and her husband, psychologist Thomas Patterson. This is an incredible story of Strathdee’s fight to save her husband’s life, which led her to rediscover a forgotten treatment for antibiotic-resistant bacteria. This unprecedented treatment saved Patterson’s life as well as several others and helped launch the Center for Innovative Phage Applications and Therapeutics (IPATH) at UC San Diego, the first phage therapy center in North America. Series: "Women in Science" [Health and Medicine] [Show ID: 34410]

Delve into the realms of predatory superbugs with infectious disease epidemiologist Steffanie Strathdee and her husband, psychologist Thomas Patterson. This is an incredible story of Strathdee’s fight to save her husband’s life, which led her to rediscover a forgotten treatment for antibiotic-resistant bacteria. This unprecedented treatment saved Patterson’s life as well as several others and helped launch the Center for Innovative Phage Applications and Therapeutics (IPATH) at UC San Diego, the first phage therapy center in North America. Series: "Women in Science" [Health and Medicine] [Show ID: 34410]

Delve into the realms of predatory superbugs with infectious disease epidemiologist Steffanie Strathdee and her husband, psychologist Thomas Patterson. This is an incredible story of Strathdee’s fight to save her husband’s life, which led her to rediscover a forgotten treatment for antibiotic-resistant bacteria. This unprecedented treatment saved Patterson’s life as well as several others and helped launch the Center for Innovative Phage Applications and Therapeutics (IPATH) at UC San Diego, the first phage therapy center in North America. Series: "Women in Science" [Health and Medicine] [Show ID: 34410]

Delve into the realms of predatory superbugs with infectious disease epidemiologist Steffanie Strathdee and her husband, psychologist Thomas Patterson. This is an incredible story of Strathdee’s fight to save her husband’s life, which led her to rediscover a forgotten treatment for antibiotic-resistant bacteria. This unprecedented treatment saved Patterson’s life as well as several others and helped launch the Center for Innovative Phage Applications and Therapeutics (IPATH) at UC San Diego, the first phage therapy center in North America. Series: "Women in Science" [Health and Medicine] [Show ID: 34410]

Delve into the realms of predatory superbugs with infectious disease epidemiologist Steffanie Strathdee and her husband, psychologist Thomas Patterson. This is an incredible story of Strathdee’s fight to save her husband’s life, which led her to rediscover a forgotten treatment for antibiotic-resistant bacteria. This unprecedented treatment saved Patterson’s life as well as several others and helped launch the Center for Innovative Phage Applications and Therapeutics (IPATH) at UC San Diego, the first phage therapy center in North America. Series: "Women in Science" [Health and Medicine] [Show ID: 34410]

A trial investigates the use of a cocktail of phages for the therapy of infections in patients with burns.

Let's cover some listener questions, including: Arthritis Trustworthy Supplement Brands HCl Causing SIBO Thyroid Antibodies Adrenal Fatigue and Phage Therapy https://drruscio.com/listener-questions-may-2018/ My new book is finally available: Healthy Gut, Healthy You. Click here to learn more: https://drruscio.com/getgutbook/ Looking for more? Check out our resource page that includes how to become a patient, how to pick up a copy of my new book, how to sign up for my clinical training newsletter, and more. https://drruscio.com/resources

Phage therapy is the next generation of medical treatment against bacterial infections, according to Jonathan Solomon, CEO of BiomX and may hold to key to curing chronic diseases such as inflammatory bowel disease (IBD) and cancer. Over 1.5 million Americans suffer from IBD and according to CBO Assaf Oron, the numbers of cases are growing rapidly. BiomX was founded by scientists with expertise in bacteriophages, or phages, which is the natural viruses that fight bacteria in the body. By sequencing strains of harmful bacteria, BiomX hopes to create effective phages to provide targeted and specific treatment of diseases caused by bacteria. The process of identifying the correct phage to attack bacteria is very complex and requires the collection of bacteria strains from many people and test various phages for effectiveness against the various strains of bacteria. BiomX is also working on ways to manipulate and strengthen phages to fight against bacteria.

Bacteriophages are viruses that infect and kill bacteria. When they were first discovered in the early part of the 20th century, there was great enthusiasm for their potential use to treat all sorts of bacterial infections. They were supplanted by antibiotics and although they remained critically important in research that led to the understanding of DNA and how it works, bacteriophages never really made it in the therapeutic world. Now that multiple-drug-resistant bacteria are becoming increasingly common, there is renewed interest in using bacteriophages to treat bacterial infection. Links: YouTube video summarizing the career and science of Félix d'Hérelle-one of the discoverers of bacteriophages Dr. Felix d'Herelle Canadian Medical Hall of Fame Laureate 2007 Detailed history of the development of bacteriophage research in Georgia A Stalinist Antibiotic Alternative from New York Times Magazine, February 6, 2000 Reprint of Twort’s initial description of a substance killing bacteria discovered while trying to grow viruses. Although Twort did not identify bacteriophages in his experiment, he believed there was some toxic entity that killed bacteria present in his experiments. An investigation on the nature of ultra-microscopic viruses1 by Twort FW, L.R.C.P. Lond., M.R.C.S. Reprint and translation of d’Herelle’s original 1917 description of bacteriophages isolated from soldiers recovering from dysentery. On an invisible microbe antagonistic to dysentery bacilli. Note by M. F. d’Herelle, presented by M. Roux. Comptes Rendus Academie des Sciences 1917; 165:373–5 Review of the non-English-language literature on bacteriophage therapy of infection Bacteriophage Therapy Antimicrob Agents Chemother. 2001 Mar; 45(3): 649–659. Review of the history bacteriophage research and its effect on scientific development and clinical medicine The Murky Origin of Snow White and Her T-Even Dwarfs Genetics 155: 481–486 (June 2000) News report from UC San Diego on treatment of the patient described in the podcast Novel Phage Therapy Saves Patient with Multidrug-Resistant Bacterial Infection 2017 JAMA Medical News article on the use of bacteriophage to treat a patient with multidrug-resistant Acinetobacter infection Phage Therapy’s Role in Combating Antibiotic-Resistant Pathogens

This Medical News podcast discusses how bacteriophage therapy might help fight antibiotic-resistant infections.

It’s a privilege to share the story of Tom Patterson, PhD, and his wife, Steffanie Strathdee, PhD, both faculty members at UC San Diego School of Medicine. In November 2015, they were vacationing in... A podcast about science and discovery at UC San Diego Health. In each episode, we bring you the story of one project, one discovery or one scientist.